2 December 2025 - Enrolling patients in the GLEAM trial for SC291 in B-cell mediated auto-immune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025.

Sana Biotechnology today announced that the US FDA granted fast track designation for SC291 in relapsed/refractory systemic lupus erythematosus, which includes extra-renal lupus and lupus nephritis.

Read Sana Biotechnology press release